CClinicalTrials.gg
Active, not recruitingNCT07147192Updated Sep 2, 2026

Feasibility Study of an Accommodating IOL Design

An interventional study of AAL-FAIOL and BAL-FAIOL in Aphakia, sponsored by Alcon Research. Active, not recruiting at 4 sites in 4 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Alcon Research · Not applicable, Interventional, and Device feasibility

Phase
Not applicable
Study type
Interventional
Enrollment
85
Allocation
Non-randomized
Ages
22 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to assess safety and explore usability and effectiveness of the test product, AAL-FAIOL. This study will be conducted in Central America.

Read the detailed description

This study will enroll adult subjects who require cataract surgery in both eyes. One eye will receive the AAL-FAIOL and the other eye will receive the BAL-FAIOL. The two eye surgeries will be separated by 14-35 days. Subjects will attend follow up visits for approximately 1 year. If needed, the AAL lens may be adjusted after surgery with a laser to help give the participant better vision.

02

Conditions studied

  • Aphakia

Browse trials for

Keywords

  • Cataract
03

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Able to understand and sign an Informed Consent Form.
  • Willing and able to attend all scheduled study visits required per protocol.
  • Diagnosed with bilateral cataracts requiring removal by phacoemulsification.
  • Preoperative corneal astigmatism equal to or less than 1.50 diopter (D) in both eyes.
  • Other protocol-defined inclusion criteria may apply.

Key Exclusion Criteria:

  • Women of childbearing potential who are pregnant, intend to become pregnant during the study, or are breastfeeding.
  • Taking medications that could increase risk or may affect accommodation.
  • Eye conditions as specified in the protocol, including glaucoma or ocular hypertension.
  • Medical conditions that could increase operative risk as specified in the protocol.
  • Other protocol-defined exclusion criteria may apply.
04

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (estimated)

Study arms

  • Experimental
    AAL-FAIOL

    The clouded lens will be removed by phacoemulsification, after which the AAL-FAIOL will be implanted in one eye.

    Device: AAL-FAIOL · Procedure: Phacoemulsification

  • Experimental
    BAL-FAIOL

    The clouded lens will be removed by phacoemulsification, after which the BAL-FAIOL will be implanted in one eye.

    Device: BAL-FAIOL · Procedure: Phacoemulsification

Interventions

  • DeviceAAL-FAIOL

    Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject. Laser energy to specified locations can be used to allow a change in power for far distances.

  • DeviceBAL-FAIOL

    Intraocular lens (IOL) placed into the lens capsule of the eye during cataract surgery. IOLs are implantable medical devices intended for long-term use over the lifetime of the pseudophakic subject.

  • ProcedurePhacoemulsification

    Cataract surgery technique that uses ultrasound to break up and remove the clouded lens, allowing for intraocular lens (IOL) implantation.

05

What researchers measure

Primary outcomes

  1. Cumulative ocular adverse events (AEs), including Secondary Surgical Interventions (SSIs)

    The number of adverse events, including SSI's, will be calculated. An SSI is a subsequent operation performed to address issues or complications arising from a previous surgical procedure. AEs will be collected starting at Day 0 after informed consent. SSIs will be collected starting Day 1.

    Time frame: From Day 0 up to Month 12

06

Study locations

4 sites
  • Clinica 20/20
    San José, Costa Rica
  • Instituto Espaillat Cabral
    Santo Domingo, Dominican Republic
  • Centro Panamericano de Ojos / Clinica Lopez Beltran
    San Salvador, El Salvador
  • Panama Eye Center
    Panama City, Panama
07

References and documents

Related links

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT07147192
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Aug 29, 2025
Start date
Dec 3, 2025
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 2, 2026

Study contacts

Clinical Trial Lead, Surgical
study director · Alcon Research, LLC

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion